PACCT1 Program for the Assessment of Clinical Cancer Tests: Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
Many women with early-stage breast cancer are advised to receive chemotherapy in addition to hormonal therapy, yet research has not shown that chemotherapy benefits all of them equally. The TAILORx trial will use the Oncotype DX test results to assign patients to either 1)chemotherapy + hormonal therapy or 2)hormonal therapy alone based on their Oncotype DX Recurrence Score(RS).
- women with invasive breast cancer that is estrogen and/or progesterone receptor positive - negative lymph nodes - no Her2+ breast cancer - tumor size 1.1-5 cm (or 5 mm-1.0 cm if unfavorable features) - must be agreeable to initiate standard chemotherapy and hormonal therapy as adjuvant treatment - must be between 18-75 years old - good physical condition and good organ function - no prior chemo or radiation for this malignancy - no prior history of breast cancer or other prior malignancies within the past 5 yrs
Pts with RS of 11-25 will be randomized to receive either chemo/hormonal therapy or hormonal therapy alone. The choice of which type of chemotherapy and hormonal therapy is given will be determined by you and your physician.
07/29/2014 04:02 AM